AC Immune SA
ACIU
View Detailed Chart
3.180USD
+0.150+4.95%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
319.30MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.95%
5 Days
-1.85%
1 Month
+6.00%
6 Months
+69.15%
Year to Date
+17.78%
1 Year
+18.66%
View Detailed Chart
TradingKey Stock Score of AC Immune SA
Currency: USD Updated: 2025-12-22Key Insights
AC Immune SA's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 156/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AC Immune SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Strong Buy
Current Rating
9.000
Target Price
+223.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
AC Immune SA Highlights
StrengthsRisks
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 631.15% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.97M.
Fairly Valued
The company’s latest PE is -3.54, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.95M shares, increasing 0.03% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 4.76K shares of this stock.
AC Immune SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
AC Immune SA Info
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Ticker SymbolACIU
CompanyAC Immune SA
CEOPfeifer (Andrea)
Websitehttps://www.acimmune.com/
FAQs
What is the current price of AC Immune SA (ACIU)?
The current price of AC Immune SA (ACIU) is 3.180.
What is the symbol of AC Immune SA?
The ticker symbol of AC Immune SA is ACIU.
What is the 52-week high of AC Immune SA?
The 52-week high of AC Immune SA is 4.000.
What is the 52-week low of AC Immune SA?
The 52-week low of AC Immune SA is 1.430.
What is the market capitalization of AC Immune SA?
The market capitalization of AC Immune SA is 319.30M.
What is the net income of AC Immune SA?
The net income of AC Immune SA is -50.92M.
Is AC Immune SA (ACIU) currently rated as Buy, Hold, or Sell?
According to analysts, AC Immune SA (ACIU) has an overall rating of --, with a price target of 9.000.
What is the Earnings Per Share (EPS TTM) of AC Immune SA (ACIU)?
The Earnings Per Share (EPS TTM) of AC Immune SA (ACIU) is -0.898.
Related Instruments
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%Popular Symbols
